GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OS Therapies Inc (AMEX:OSTX) » Definitions » Common Stock

OSTX (OS Therapies) Common Stock : $0.02 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is OS Therapies Common Stock?

OS Therapies's quarterly common stock increased from Jun. 2024 ($0.01 Mil) to Sep. 2024 ($0.02 Mil) but then stayed the same from Sep. 2024 ($0.02 Mil) to Dec. 2024 ($0.02 Mil).

OS Therapies's annual common stock stayed the same from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.02 Mil).


OS Therapies Common Stock Historical Data

The historical data trend for OS Therapies's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OS Therapies Common Stock Chart

OS Therapies Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Common Stock
0.01 0.01 0.01 0.02

OS Therapies Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.02 0.02

OS Therapies Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


OS Therapies Business Description

Traded in Other Exchanges
N/A
Address
15825 Shady Grove Road, Suite 135, Rockville, MD, USA, 20850
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.